Physician profile
Rahul Gokhroo
NPI 1184987372
$4,770.51
in general payments reported to CMS, 2019-2025
29 companies · $398 in 2025
The $398 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,626 · 2020: $282 · 2021: $79.14 · 2022: $1,855 · 2023: $355 · 2024: $177 · 2025: $398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $929.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $929.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,685.75 | 2019-2023 | Jot Dx, Mitraclip, Diamondback Coronary |
| Abiomed | $371.86 | 2019-2024 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $358.34 | 2020-2023 | Lifevest |
| Boston Scientific Corporation | $311.80 | 2019 | |
| Philips North America LLC | $272.25 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $209.13 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $194.90 | 2021-2025 | |
| Medtronic Vascular, INC. | $194.10 | 2019 | |
| Bard Peripheral Vascular, INC. | $183.10 | 2019-2022 | |
| Imperative Care, INC | $133.71 | 2025 | Symphony Catheter |
| Merck Sharp & Dohme LLC | $114.88 | 2022-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Novo Nordisk INC | $113.11 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Cardiovascular Systems INC. | $107.25 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $59.63 | 2022-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.00 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $50.47 | 2022-2023 | Repatha |
| Recor Medical INC | $49.35 | 2025 | Paradise Ultrasound Renal Denervation System |
| E.R. Squibb & Sons, L.L.C. | $45.19 | 2022-2025 | Camzyos |
| Penumbra, INC. | $42.51 | 2020 | |
| Corcept Therapeutics | $33.02 | 2025 | Korlym |
| Teleflex LLC | $31.91 | 2019 | |
| Shockwave Medical, INC | $27.93 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Chiesi USA, INC. | $23.71 | 2019 | |
| Terumo Medical Corporation | $22.59 | 2019 | |
| Glaxosmithkline, LLC. | $17.96 | 2025 | Shingrix |
| Pfizer INC. | $16.84 | 2023 | |
| Exact Sciences Corporation | $16.60 | 2025 | Cologuard Collection Kit |
| Modernatx, INC. | $14.96 | 2025 | Mresvia |
| Ekos Corporation | $12.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rahul Gokhroo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.